首页> 外文期刊>Chinese Jouranl of Integrative Medicine >Clinical Study on the Effect of Shengxueling on Idiopathic Thrombocytopenic Purpura
【24h】

Clinical Study on the Effect of Shengxueling on Idiopathic Thrombocytopenic Purpura

机译:生疏灵对特发性血小板减少性紫癜影响的临床研究

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: To observe the clinical effect of Shengxueling (SXL) on idiopathic throm-bocytopenic purpura (ITP), and study the possible mechanism. Methods: Eighty-six cases of ITP were randomly divided into two groups. The SXL group, 56 patients treated with SXL, a traditinal Chinese medicine and 30 patients administered with prednisone were taken as control. Each group took drugs for 3 months and was under follow-up observation. Results: In the SXL group, the total effective rate was 85.71% , similar to prednisone 83.33% (P >0.05) for 3 months, but the total effective rate of SXL (91.07%) were obviously better than that of the control group (53.33%) (P< 0.01) for 6 months and had no obvious adverse reaction. The patients bleeding was alleviated or stopped, the general condition was improved. At the same time, blood platelet count (PLT) was increased, platelet associated immunoglobulin (PAIg) and interleukin-4 (IL-4) were markedly dropped, the level of natural killers cells activity (NKa) increased, the rate of T lymphocyte subsets gradually returned to normal level. Megakaryocyte tended to maturation on bone marrow smear after treatment. All differences above were statistically significant. Conclusion: SXL is an effective and safe medicine for ITP. Its mechanism could regulate cytoimmune, inhibit platelet antibody to reduce the destruction of platelet, increase the number of platelet, promote the division and maturation of megakaryocyte, facilitate the production and release of platelet, lower the fragility of capillary, prevent and cure hemorrhagic tendency.
机译:目的:观察升雪灵(SXL)治疗特发性血小板减少性紫癜(ITP)的临床疗效,并探讨可能的机制。方法:将86例ITP患者随机分为两组。以SXL组,SXL治疗56例,传统中药和泼尼松30例为对照组。每组服药3个月,并进行随访观察。结果:SXL组3个月总有效率为85.71%,与泼尼松83.33%相似(P> 0.05),但SXL总有效率为91.07%,明显优于对照组(P <0.05)。 53.33%)(P <0.01)持续6个月且无明显不良反应。患者的出血得到缓解或停止,总体状况得到改善。同时,血小板计数(PLT)增加,血小板相关免疫球蛋白(PAIg)和白细胞介素4(IL-4)明显下降,自然杀伤细胞活性(NKa)水平升高,T淋巴细胞率子集逐渐恢复到正常水平。治疗后,巨核细胞在骨髓涂片上趋于成熟。以上所有差异均具有统计学意义。结论:SXL是ITP的一种安全有效的药物。其机制可调节细胞免疫,抑制血小板抗体,减少血小板破坏,增加血小板数量,促进巨核细胞分裂和成熟,促进血小板的产生和释放,降低毛细血管的脆性,预防和治愈大出血的趋势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号